Original Articles: EpidemiologyLong-term relative survival from melanoma in Germany 1997–2013Brunssen, Aliciaa; Jansen, Linaj; Eisemann, Noraa; Waldmann, Annikaa,,c; Weberpals, Janickj; Kraywinkel, Klausd; Eberle, Andreae; Holleczek, Berndf; Zeissig, Sylke R.g; Brenner, Hermannh,,i,,j; Katalinic, Alexandera,,b; for the GEKID Cancer Survival Working GroupAuthor Information aInstitute for Social Medicine and Epidemiology bInstitute for Cancer Epidemiology, University of Luebeck, Luebeck cHamburg Cancer Registry, Ministry for Health and Consumer Protection, Hamburg dGerman Centre for Cancer Registry Data, Robert Koch Institute, Berlin eCancer Registry of Bremen, Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen fSaarland Cancer Registry, Saarbruecken gCancer Registry of Rhineland-Palatinate, Mainz hDivision of Preventive Oncology, National Center for Tumor Diseases (NCT) iGerman Cancer Consortium (DKTK) jDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany Received 11 December 2017 Accepted 17 June 2018 Correspondence to Alicia Brunssen, Institute for Social Medicine and Epidemiology, University of Luebeck Ratzeburger Allee 160 23562 Luebeck, GermanyTel: +49 451 5005 1210; fax: +49 451 500 1204; e-mail: [email protected] Melanoma Research: August 2020 - Volume 30 - Issue 4 - p 386-395 doi: 10.1097/CMR.0000000000000482 Buy Metrics Abstract Up-to-date melanoma relative survival (RS) estimates and trend analysis facilitate close monitoring of melanoma patients’ prognosis. This study aimed to provide recent 5-year and 10-year RS from melanoma, stratified by prognostic factors, and identify latest survival trends. Data from 12 German cancer registries were analysed. We included patients with primary cutaneous malignant melanoma (ICD-10: C43.X) diagnosed in 1997–2013 who were at least 15 years old. Five-year and 10-year RS were estimated by period analysis. For 10-year RS analyses, we excluded patients who were 75 years of age or older. Analyses were stratified by sex, age, histology, tumour stage, and body site. We included 82 901 patients, of whom 51% were women. The median age at diagnosis was 62 years. Five-year and 10-year RS in 2007–2013 were 92.4 and 90.8%, respectively. RS was higher in women. The prognosis worsened with older age and higher stage. In superficial spreading melanoma and lentigo maligna melanoma, RS was high; it was lower in nodular, acral lentiginous and ‘other’ melanoma. RS was the highest for melanoma on the arms; RS for melanoma on unknown or overlapping sites of the skin was the lowest. Five-year and 10-year RS increased significantly from 2005–2007 and 2008–2010 to 2011–2013, by 3.5 and 3.3 percentage points, respectively. For melanoma of ‘other’ histology, 5-year and 10-year RS increased significantly. Ten-year RS also increased significantly in men with superficial spreading melanoma and T4 melanoma, and in women with T3 melanoma. Melanoma RS improved, especially in certain subgroups. The reasons for improvements need to be investigated further. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.